NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

CASI Pharmaceuticals, Inc. (CASI) Stock Analysis

CASI Pharmaceuticals, Inc. (CASI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CASI

$0.14

+$0.01 (+7.58%)

Last trade April 29, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CASI with… →

CASI Key Statistics

As of Apr 29, 2026
Trading
Open
$0.13
Previous Close
$0.13
Day's Range
0.13–0.15
52-Week Range
0.74–3.09
Volume
1.03K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.89
Valuation
Market Cap
$11.85M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.02
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−183.96%
1-Year Return
−92.90%
Dividend and dates
Avg Volume
37.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CASI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−83.29%
2025−67.43%

As of April 29, 2026.

CASI Valuation vs Biotechnology Median

Median of 656 stocks
MetricCASIBiotechnology medianvs median
P/S ratio0.4415.260.0x the median
Profit margin−183.96%0.00%184.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values CASI Pharmaceuticals, Inc. (CASI) at $11.85M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 233 employees.

CASI last closed at $0.14 on April 29, 2026. That is +$0.01 (+7.58%) against the previous close. The 52-week range on file runs from $0.74 to $3.09.

Financial Health

Trailing twelve-month revenue on file is $26.85M. Profit margin runs at −183.96%. That is 184 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −3.02.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.44 times revenue. On price-to-sales that is 0 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −92.90%. Beta against the wider market is reported at 0.89. Daily returns over the trailing 1 year annualize to a volatility of 154.57%.

Growth & Income

No dividend is on file for CASI.

So far in 2026 the price is −83.29%. The record holds one complete calendar year, 2025, which returned −67.43%.

Peer Comparison

CASI Pharmaceuticals, Inc. (CASI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
CASI Pharmaceuticals, Inc. CASI $11.85M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. CASI Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of April 29, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Visit website →